BBVA USA’s Novo Nordisk NVO Stock Holding History

BBVA USA’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$4.46M	Sell	92,866 -3,518	-4%	-$170K	0.26%	82
2021 Q2	$4.04M	Buy	+96,384	New	+$3.74M	0.23%	100

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBVA USA's NVO Position: Q3 2021 in Review

BBVA USA reduced its Novo Nordisk (NVO) stake by 3.6% in Q3 2021, selling an estimated $170K and leaving 92,866 shares worth $4.46M. The position accounts for 0.26% of the portfolio, ranked #82.

BBVA USA first reported a position in NVO in Q2 2021 and has held it in 2 quarters since. 804 funds tracked by Wall St. Rank hold NVO as of Q3 2021.

BBVA USA held 92,866 shares of Novo Nordisk worth $4.46M as of Q3 2021.
BBVA USA sold 3,518 Novo Nordisk shares in Q3 2021, an estimated $170K.
Novo Nordisk made up 0.26% of BBVA USA's portfolio in Q3 2021, its #82 holding.
BBVA USA first reported a position in Novo Nordisk in Q2 2021 and has held it in 2 quarters since.
804 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.